VEGFA and non-small cell lung carcinoma: However, given the risk of increased cardiac burden due to fluid retention and edema, which are typical adverse events of anti-VEGF and anti-VEGF receptor inhibitors, caution should be exercised when administering these drugs to NSCLC patients with severe to most severe COPD.